Milan, April 22-23, 2024 Hilton Milan Hotel

Registry meetING on HIV
multidrug resistance

Contemporary antiretroviral therapy (ART) has dramatically improved the prognosis of people living with HIV (PLWH) through the achievement of durable viral suppression and immune function restoration.

However, some heavily treatment-experienced PLWH (HTE-PLWH) are unable to achieve or maintain viral suppression because of HIV-1 multi-drug resistance and/or drug intolerance. For these persons, who are at high risk of clinical pro­gression, morbidity, and mortality, the proper management of the current and future antiretroviral options is critically important.

The PRESTIGIO Registry is an observational, prospective, multicenter, annual collection of clinical and virological data and samples HTE-PLWH, regularly followed at several Italian Centers, with documented resistance to the major four clas­ses of antiretroviral drugs (NRTI, NNRTI, PI, INSTI). The aims of the PRESTIGIO Registry include the characterization of this fragile population and the creation of an interactive and multidisciplinary environment to improve the overall ma­nagement of HTE-PLWH.

The second edition of the PRESTIGIO Registry Meeting (RING) has been conceived from these premises and is a unique opportunity to describe the state of art in the field of HIV multidrug resistance and to discuss the real-life management of HTE-PLWH.

The RING Meeting is designed as a forum for basic scientists and infectious diseases specialists experienced in HIV drug resistance and management of HTE-PLWH. The RING Meeting includes some key lectures held by experts in the field and plenary discussion groups on challenging clinical experiences. We believe that this format can improve interaction and lively participation and we look forward to seeing you at the RING Meeting!